The progress reports on the development of therapies of Duchenne muscular dystrophy.
The roots of the progress reports on the development of therapies for Duchenne muscular dystrophy (DMD) that since 2000 have been produced at Breitnau/Germany and distributed to the parents of DMD patients cover over 30 years of continual occupation with this disease. The beginning was marked by the development of an early detection programme for the genetic disposition for DMD in infant boys. The next step was the organisation of workshops on the management of DMD and the writing of progress reports on these and other relevant conferences. Getting acquainted with the ideas of the protagonists in the research field by holding interviews was a decisive prerequisite for this activity. This took place in tandem with the development of a new kind of multiplex "family letters" that attempted to answer frequently asked questions to many DMD families at the same time. When--with the beginning of the new millennium--the endeavours towards gene therapies for DMD started to boom all over the scientific world, progress reports designed to keep the families informed about research on DMD treatment were added to the family letters. These reports that give an account of the latest state of the research are written in a plain language that can be understood by laypersons. In the meantime the reports have adopted the character of reviews that are updated annually. They are written in English and German and translated into Spanish and many other languages.
Scheuerbrandt
G
G
Testlaboratorium Breitnau, Germany. gscheuerbrandt@t-online.de
D003142:Communication; D003226:Congresses as Topic; D034742:Electronic Mail; D005091:Exons / Q000235:genetics; D015316:Genetic Therapy; D006801:Humans; D007231:Infant, Newborn; D020388:Muscular Dystrophy, Duchenne / Q000235:genetics / Q000628:therapy*; D015997:Neonatal Screening; D010817:Physician-Patient Relations